Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Glide path describes how a target date fund changes its asset mix as the target year approaches, balancing risk and growth for your retirement.
25,488 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
ProShares Ultra Bloomberg Crude Oil 2x (UCO) has surged about 125% this year, yet traders warn a hidden structural ri...
Intel stock climbs about 5% after word that the company is in talks to acquire AI accelerator startup Tenstorrent, re...
Ad-tech leaders Trade Desk and AppLovin face renewed scrutiny in 2026 as AI investments pressure margins and trigger ...
AMD's quarterly results show data-center strength lifting the growth story. This piece maps a 5-year prediction stock...
New York Governor Hochul’s decision to pause autonomous for-hire vehicle expansion outside NYC hits Waymo and Tesla’s...
A caller in his 60s with a six-figure income and no retirement savings since 2008 receives a blunt reality check on T...
As Q2 2026 gains momentum, XRP, Solana, and BNB post modest climbs. Investors eye price thresholds and upcoming catal...
Rivian stock moved higher this week without a formal press release, boosted by direct investor outreach and renewed i...
Jim Cramer remains wary of Salesforce as growth slows and CIOs shift budgets to less expensive software. He argues th...
Axon is set to report Q4 2025 results after the close, as Wall Street weighs software momentum, AI-era bookings, and ...
Arm is venturing into in house silicon for AI workloads, a bold move that could redefine its growth path. This articl...